We provide you with 20 years of free, institutional-grade data for ALGS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALGS. Explore the full financial landscape of ALGS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Aligos Therapeutics, Inc(NASDAQ:ALGS) 
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic h...
Website: http://www.aligos.com
Founded: 2018
Full Time Employees: 73
CEO: Lawrence M. Blatt
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ALGS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.